Mail Us

info@pharmasolutions-int.com

Contact Us

+971 4220 7991

Gemnil 200mg & 1gm injection Vial

Gemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolized intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalyzing the reactions that produce deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP reduces the concentration of deoxynucleosides in general and, in particular, dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).

Share Now

Additional Information

NameGemnil
DescriptionGemcitabine (dFdC), which is a pyrimidine antimetabolite, is metabolized intracellularly by nucleoside kinase to the active diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. The cytotoxic effect of gemcitabine is due to inhibition of DNA synthesis by two mechanisms of action by dFdCDP and dFdCTP. First, dFdCDP inhibits ribonucleotide reductase, which is uniquely responsible for catalyzing the reactions that produce deoxynucleoside triphosphates (dCTP) for DNA synthesis. Inhibition of this enzyme by dFdCDP reduces the concentration of deoxynucleosides in general and, in particular, dCTP. Second, dFdCTP competes with dCTP for incorporation into DNA (self-potentiation).
Active IngredientGemcitabine
IndicationGemcitabine in combination therapy is indicated for the following cancer types:

  • Advanced or metastatic bladder cancer
  • Advanced or metastatic adenocarcinoma of the pancreas.
  • Advanced or metastatic non-small cell lung cancer (NSCLC).
  • Advanced or metastatic epithelial ovarian carcinoma

Locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Strengths200mg & 1gm injection Vial
Business PartnerAuromedics
OriginUSA

Related Products

Disclaimer

Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the  respective local health authority or contracted by the MAH to supply to the end users  on a named patient basis. Some products such  as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.

[elfsight_whatsapp_chat id='1']